Former employees of AstraZeneca R&D, Lund, Sweden.
Pulm Pharmacol Ther. 2012 Oct;25(5):399-406. doi: 10.1016/j.pupt.2012.08.001. Epub 2012 Aug 16.
Preclinical in vivo models of lipopolysaccharide (LPS) -induced acute lung injury are commonly used to recapitulate pathophysiological features of chronic obstructive pulmonary disease and acute exacerbations. The LPS-induced lung inflammation is well described; however, whether the inflammatory response relates temporally to specific alterations in lung function has not been elucidated. We have investigated the effects of acute LPS inhalation in mice up to 96 h post LPS. Quantitation of inflammatory cells and inflammatory mediators in bronchoalveolar lavage fluid and non-invasive and invasive lung function measurements were performed at corresponding time points. The inhibitory effect of the glucocorticoid, budesonide, on LPS-induced lung inflammation and lung function was determined. LPS inhalation induced distinct histopathological changes, and infiltration of inflammatory cells to the lungs peaked at 48 h. At this time point, significantly increased inflammatory mediators and significantly altered lung capacity and mechanics parameters were observed. Budesonide given per os prevented the LPS-induced lung inflammation and lung dysfunction. These results demonstrate a temporal relationship between the peak of inflammatory cell influx and significant impairment of lung function, suggestive of a causative role of inflammation. These results allow better understanding of the functional consequences of lung inflammation in respiratory diseases.
脂多糖(LPS)诱导的急性肺损伤的临床前体内模型常用于重现慢性阻塞性肺疾病和急性加重期的病理生理特征。LPS 诱导的肺炎症反应已有很好的描述;然而,炎症反应是否与特定的肺功能改变有关尚不清楚。我们研究了 LPS 吸入对 LPS 后 96 小时内小鼠的影响。在相应的时间点,对支气管肺泡灌洗液中的炎性细胞和炎性介质进行定量,并进行非侵入性和侵入性肺功能测量。还确定了糖皮质激素布地奈德对 LPS 诱导的肺炎症和肺功能的抑制作用。LPS 吸入引起明显的组织病理学改变,炎性细胞浸润肺部在 48 小时达到高峰。此时,观察到炎症介质显著增加,肺容量和力学参数明显改变。口服给予布地奈德可预防 LPS 诱导的肺炎症和肺功能障碍。这些结果表明,炎症细胞浸润的峰值与肺功能显著受损之间存在时间关系,提示炎症起因果作用。这些结果使人们更好地了解呼吸道疾病中肺炎症的功能后果。